Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2004

View Archived Issues

Artekin may contribute to control of multidrug-resistant malaria

Enrollment complete in phase IV Visicol constipation study

Preclinical evidence for the antiviral efficacy of interferon alpha in SARS

Duloxetine improves voiding and quality of life of women with stress urinary incontinence

Clinical development of CAB-175 discontinued

Genzyme to acquire Ilex Oncology

Reorganization of indiplon agreements

Active Biotech discontinues discovery projects, focuses on development

Biovail acquires rights to novel formulations of eprosartan and carvedilol

Reolysin program update

Integrin alphavbeta3 antagonist and bone resorption inhibitor characterized for further development

Randomization completed in candesartan diabetic retinopathy program

Pharmacological characterization of novel DPP IV inhibitor K-579

Successful completion of first phase I trial for nebulized rAAT

Identification of neural stem cells in adult human brain

Improved response found in vitiligo patches with tacrolimus and excimer laser

Four related series of LDL receptor upregulators presented by GSK

New antibacterial oxazolidinones presented by Orchid researchers

Novel HDAC inhibitors prepared and tested by 4SC and G2M scientists

New glucosylceramide synthase inhibitors identified at Oxford Glycosciences

Aventis claims the preparation and use of novel cysteine protease inhibitors

New xanthine oxidase inhibitors for inflammation, reperfusion disorders and gout

Uriach presents immunomodulators and proapoptotic agents in a recent patent

Two novel series of glycogenphosphorylase a inhibitors under study at Aventis

Sinus and Allergy Health Partnership guidelines recommend Omnicef

Kirin announces phase I clinical trial of KRN-125 and other recent developments

Preclinical data supports use of INGN-241 regimens for lung, breast cancer

Satraplatin shows in vitro efficacy in tumor cells resistant to Taxotere and Taxol

Advanced Viral Research reports in vitro biologic effects of AVR-118

Approvable letter for Estorra

Zadaxin shows efficacy in preclinical invasive aspergillosis study

Investigation of Viagra for FSAD to close

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...